1. Home
  2. ATYR vs ASRT Comparison

ATYR vs ASRT Comparison

Compare ATYR & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.78

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

HOLD

Current Price

$0.78

Market Cap

75.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATYR
ASRT
Founded
2005
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
75.1M
IPO Year
2015
1997

Fundamental Metrics

Financial Performance
Metric
ATYR
ASRT
Price
$0.78
$0.78
Analyst Decision
Buy
Strong Buy
Analyst Count
6
1
Target Price
$8.75
$3.00
AVG Volume (30 Days)
2.6M
438.8K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$190,000.00
$137,354,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$18,728.88
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9.22
52 Week Low
$0.64
$0.51
52 Week High
$7.29
$1.01

Technical Indicators

Market Signals
Indicator
ATYR
ASRT
Relative Strength Index (RSI) 43.35 47.26
Support Level $0.70 $0.75
Resistance Level $0.83 $0.80
Average True Range (ATR) 0.06 0.04
MACD 0.03 0.01
Stochastic Oscillator 57.87 74.57

Price Performance

Historical Comparison
ATYR
ASRT

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: